ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
New Data Shows that MammaPrint Substantially Impacts how Breast Cancer Patients in Germany are Treated
PRIMe trial included 452 women at 27 centers in Germany, Austria, and Switzerland Based on the outcome of the MammaPrint test, 28.4% of patients’ treatment plans were changed, compared to conventional clinico-pathological tests; preventing under Read More
Three New Studies Presented at San Antonio Breast Cancer Symposium Further Demonstrate Value of MammaPrint and BluePrint in Individualizing Treatment for Breast Cancer Patients
Long-term follow-up of early-stage breast cancer patients shows significant difference in how gene expression-based tests classify patients for adjuvant chemotherapy treatment, finds MammaPrint® the best predictor of distant cancer recurrence MINT trial confirms stratification of Read More
Agendia Responds to IQWiG Assessment for Reimbursement of Gene Expression-based Breast Cancer Recurrence Tests
IRVINE, CA and AMSTERDAM, 5 December 2016 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, notes the recommendation of Germany’s Institute for Quality and Efficiency in Healthcare (IQWiG) to delay Read More
Agendia’s MammaPrint and BluePrint Tests Highlighted in Multiple Presentations at the 2016 San Antonio Breast Cancer Symposium, Adding Further Clinical Utility
Agendia will also host two additional educational opportunities for physicians and patient advocates during this year’s conference IRVINE, CA and AMSTERDAM – 2, December 2016 – Agendia, Inc., a world leader in personalized medicine and Read More
